🇺🇸 FDA
Patent

US 11299476

Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof

granted A61PA61P25/18A61P25/24

Quick answer

US patent 11299476 (Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P25/18, A61P25/24, A61P25/36